Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2009, Pages 587-592

  Niewoehner, Dennis E ^a   Lapidus, Robert ^b   Cote, Claudia ^c   Sharafkhaneh, Amir ^d   Plautz, Mark ^a   Johnson, Philip ^e   Kesten, Steven ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Rocky Mountain Center for Clinical Research   (United States)

^c Bay Pines VA Medical Center   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Clinical trial; COPD; Ipratropium albuterol; Tiotropium

Indexed keywords

IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; LOWER RESPIRATORY TRACT DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SPIROMETRY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SPIROMETRY; TREATMENT OUTCOME;

EID: 71249140632     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.08.006     Document Type: Article

References (19)

1. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 105 (1994) 1411-1419
2. Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 112 (1997) 1514-1521
3. From the. Global Strategy for the Diagnosis, Management and prevention of copd, global initiative for chronic obstructive lung disease (GOLD). Available from (2008). http://www.goldcopd.org
4. Gross N.J. Tiotropium bromide. Chest 126 (2004) 1946-1953
5. Barr R.G., Bourbeau J., Camargo C.A., and Ram F.S.F. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61 (2006) 854-862
6. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San Pedro G., ZuWallack R.L., et al. A long-term evaluation of once-daily tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
7. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
8. Maltais F., Hamilton A., Marciniuk D., Hernandez P., Sciurba F.C., Richter K., et al. Improvements in symptom-limited exercise performance over eight hours with once-daily tiotropium in patients with COPD. Chest 128 (2005) 1168-1178
9. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper Jr. A.D., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a long-acting inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med 143 (2005) 317-326
10. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
11. Vincken W., van Noord J.A., Greefhorst A.P.M., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
12. Briggs Jr. D.D., Covelli H., Lapidus R., Bhattycharya S., Kesten S., and Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 18 (2005) 397-404
13. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 2 (2005) 214-222
14. Morris J.F., Koski A., Temple W.P., Claremont A., and Thomas D.R. Fifteen year interval spirometric evaluation of the Oregon predictive equations. Chest 93 (1988) 123-127
15. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardization of spirometry. Eur Respir J 26 (2005) 319-338
16. Mahler D.A., Donohue J.F., Barbee R.A., Goldman M.D., Gross N.J., Wisniewski M.E., et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115 (1999) 957-965
17. Dahl R., Greefhorst L.A., Nowak D., Nonikov D., Nonikov V., Byrne A.M., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
18. Oostenbrink J.B., Rutten-van Molken M.P., Al M.J., Van Noord J.A., and Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 23 (2004) 241-249
19. Make B., Hanania N.A., ZuWallack R., Kalberg C., Emmett A., Brown C.P., et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 27 (2005) 531-542